South Korean pharmaceutical firms LG Chem Ltd. and JW Pharmaceutical Corp. are recouping and pressing on with their respective novel gout drugs internationally, with each having faced regulatory setbacks from IND rejections overseas.
On the back of what Arthrosi Therapeutics LLC has called “remarkable efficacy and safety” data from a phase IIb trial of AR-882, a next-generation URAT1 inhibitor for treating gout, the company has padded its coffers with a $75 million series D round led by Guangrun Health Industry Co. Ltd. and backed by investors that include Reichstein Biotech Co. Ltd., a subsidiary of Arthrosi’s China joint venture partner Apichope Pharmaceuticals.
South Korea’s JW Pharmaceutical Corp. announced a redo of its IND application to the Taiwan FDA on June 27 for its phase III trial on gout treatment URC-102 (epaminurad). The second filing comes in response to a regulatory rejection in March citing a problem with the proposed reference drug.
Researchers have ameliorated both monogenic and complex inflammation-driven diseases through transplantation of hematopoietic stem cells with an inserted IL-1 receptor antagonist (IL-1RA) gene. The team showed that in animal models the transplanted cells worked better than monoclonal antibodies to reduce symptoms in systemic autoinflammatory diseases (SAIDs), a group of childhood-onset, lifelong diseases that vary in severity depending on the underlying mutation, but can be life-threatening.
Innovent Biologics Inc. has in-licensed LG Chem Ltd.’s tigulixostat (LC-350189), a late-stage non-purine xanthine oxidase inhibitor for managing chronic hyperuricemia in patients with gout, in a deal worth up to $95 million.
Innovent Biologics Inc. has in-licensed LG Chem Ltd.’s tigulixostat (LC-350189), a late-stage non-purine xanthine oxidase inhibitor (XOI) for managing chronic hyperuricemia in patients with gout, in a deal worth up to $95 million.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has presented solute carrier family 22 member 12 (SLC22A12) inhibitors reported to be useful for the treatment of gout and hyperuricemia.
Chengdu Baiyu Pharmaceutical Co. Ltd. has disclosed NLRP3 inflammasome inhibitors acting as pyroptosis inhibitors reported to be useful for the treatment of gout, Alzheimer's disease, atherosclerosis, diabetes, psoriasis, rheumatoid arthritis, graft-vs.-host disease and familial cold urticaria syndrome.
Inventisbio Co. Ltd. has raised ¥2.084 billion (US$296 million) in an IPO on Shanghai’s STAR Market priced at ¥18.12 per share, though its stock saw a disappointing debut, opening at ¥14 per share on the first trading day July 25 and closing at $15.29, for a drop of 15.6%. The stock closed Aug. 1 at ¥14.42.
Inventisbio Co. Ltd. has raised ¥2.084 billion (US$296 million) in an IPO on Shanghai’s STAR Market priced at ¥18.12 per share, though its stock saw a disappointing debut, opening at ¥14 per share on the first trading day July 25 and closing at $15.29, for a drop of 15.6%. The stock closed Aug. 1 at ¥14.42.
